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abstract
Solid dispersions of nifedipine prepared with two hydrophilic carrier systems, Gelucire (44/14)/PEG 600 and PVP (K12-K25)/
PEG 6000 by fusion or fusion/solvent method were characterized by thermal analysis for comparisons. Results demonstrated that both
carrier systems were able to prohibit the crystallization of nifedipine after the mixture melted at a higher temperature at a ratio exceeding
50%. The extent of forming amorphous nifedipine due to the inhibition of crystallization, also raised with the increasing ratio of the
carrier. When mixing with PEG 6000 at a ratio of 3 : 1, the melting temperature of nifedipine dropped to 110°C. Dissolution tests further
demonstrated that nifedipine, once fused with these carriers, possessed an enhanced dissolution rate. As to the Gelucire (44/14)/PEG 600
system, the dissolution rates from those samples prepared at a higher temperature were faster than those prepared at the melting point
of Gelucire. The dissolution rate increased with the amount of Gelucire added in the preparation. For the PVP/PEG 6000 carrier system,
the dissolution rate of nifedipine increased with the amounts of both PVP and PEG 6000. However, a slower dissolution rate was also
noted resulted from higher molecular weight of PVP.
Key words: solid dispersion, fusion, nifedipine, thermal analysis, dissolution

Introduction
The rate-determining step in the absorption process
for poorly water-soluble drugs lies in their dissolution rate
in gastrointestinal fluids rather than the rapidity of their
diffusion across the gut wall(1). It is a major concern to
improve the water solubility of insoluble and slightly soluble
drugs. Crystalline drugs or excipients can be partially or
completely transformed into metastable amorphous forms
during processes such as milling, spraying, and lyophilization, commonly used in the manufacture of pharmaceutical
solids(2,3). The solubility, dissolution rate, and bioavailability of low-solubility drugs can be improved if the crystalline state is transformed into an amorphous one(4). This
is because a lower energy barrier needs to be overcome for
a highly disordered amorphous material to enter solution
than that for a structured crystalline solid has. To form a
solid dispersion, one or more ingredients are dissolved or
melted with inert carriers, including physiological surfactants(4), polymers(5), and other glass-formation solids. This
* Author for correspondence. Tel & Fax: +886-2-23771942;
E-mail: mingsheu@tmu.edu.tw

is one of several techniques used to improve drug dissolution properties.
The goal of solid dispersions formation for any waterinsoluble drug is to modify the crystalline form or to produce
an amorphous form of the drug substances. The critical step
in this process is to make the solid form of the drug substance
dissolve or melt in the presence of hydrophilic carriers that
shall prevent the formation of original crystalline structure,
or transform it into a different crystalline form with a better
solubility after solvent evaporation or after cooling. Traditionally, this is accomplished by dissolving the crystalline
drug substance in a suitable solvent or mixture capable of
dissolving the hydrophilic carriers (solvent method) or by
heating both to melt (fusion method). Both methods have
their own shortcomings. Solvents present health and environmental hazards. The high cost of disposal or recycling of
large amount of solvents is a major concern if this method is
employed to prepare solid dispersions. Minimizing or eliminating the usage of solvents will make this method more
feasible. In the fusion method, a practical heating device
should have a large enough capacity for scaled-up production and can also maintain a higher temperature. It would
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be beneficial to lower the fusion temperature for melting(6).
Nifedipine, a calcium channel blocker, is usually used
in the treatment of a variety of cardiovascular diseases, such
as angina pectoris and hypertension(7). It is a photosensitive
and poorly water-soluble drug with low bioavailability when
orally administered in crystalline form(8). To improve the
dissolution rate, solid dispersions of nifedipine with watersoluble carriers such as urea(9,10), sucrose ester(11), solid
polyethylene glycol (PEG)(9,10,12-14), polyvinylpyrrolidone
(PVP)(10,14-16), polyvinyl acetate (PVA)(16), polyvinylpyrrolidone-co-vinylacetate (PVPVA)(14), Eudragit EPO(14),
hydroxylpropylmethylcellulose (HPMC)(16,17), hydroxypropylmethylcellulose phthalate (HPMCP)(18), poloxamer(12,19,20), polyethylene oxide (PEO)(21), Gelucire(19),
vitamin E TPGS(13), solutol HS-15(13), and insoluble carriers
such as crospovidone(22) have been developed. Nevertheless, many solid dispersions were prepared by the solvent
method(12,23-28), which raised both the environmental and
health concerns discussed above.
In this study, solid dispersions of nifedipine with
various water-soluble polymers as the combined carriers
were prepared by a fusion method at low temperature or by a
fusion/solvent method to minimize the quantities of solvents
used. Based on the analysis by differential scanning calorimetry, phase diagrams were constructed to examine the influence of carriers on the change in fusion temperatures. Glass
transition temperatures were obtained to understand the
effects of carriers on the formation of the amorphous form
of the model drug. Their dissolution profiles were examined
with the aid of several additives to minimize the common
tendency to aggregate, which occurred often during solid
dispersions preparation with hydrophilic polymers.

MATERIALS AND METHODS
I. Materials
Nifedipine was obtained from Sunlite Chemical
Industry (Japan). Gelucire 44/14 was supplied by Gattefosse (France). Gelucire® excipients are unique and consistent compositions of saturated polyglycolized glycerides,
consisting of mono-, di- and tri-glycerides of saturated fatty
acids, and of mono- and di-fatty acid esters of PEG. A Gelucire® is characterized by two values: its melting point and
its hydrophilicity (by its HLB value), which determine its
bio-pharmaceutical properties. These two figures are used
to identify a Gelucire®: Gelucire® 44/14, for example, has
a nominal melting point of 44°C and an HLB value of 14.
PVP, K12-K30, was provided by ISP (Wayne, New Jersey,
USA). HPMC, 6.5 cps, was obtained from Shin-Etsu (Tokyo,
Japan). PEG 600 and PEG 6000 were of reagent grade and
supplied by Merck (Darmstadt, Germany). Tween 80 was
from Riedel-de Haën (Germany). Ethanol was from the
Bureau of Wine and Tobacco Monopoly (Taiwan). All other
materials were of reagent grade or better.

II. Analysis of Differential Scanning Calorimetry (DSC) and
Phase Diagrams
DSC analyses were carried out on a DSC Pyris 1
(Perkin Elmer, USA). Approximately 10 mg of samples were
heated at a rate of 10°C/min to 200°C (1st run). The fused
samples were subsequently rapidly cooled to 10°C at a rate of
40°C/min, and then reheated to 200°C at a rate of 10°C/min
(2nd run). The melting point was read at the peak of the line.
Indium was used as the calibration standard.
Thermal analysis of a number of mixtures of nifedipine-Gelucire 44/14, nifedipine-PEG 600, or nifedipine(Gelucire 44/14 : EG 600 = 4 : 1) of various compositions
was conducted on the same DSC instrument (Pyris-1, Perkin
Elmer). A phase diagram is composed of two lines. The line
at the lower temperature is called the solidus line, which is
obtained when mixtures begin to melt. The other line, called
the liquidus line, is obtained when all mixtures have melted.
III. Preparation of Solid Dispersions
Solid dispersions of the PVP/PEG 6000 system were
prepared by a fusion-solvent method. PEG 6000 and nifedipine were mixed and heated to a temperature high enough
to melt both (110 - 170°C). A PVP/ethanol solution (50%
w/w) was then added, and the dispersion was continually
heated and stirred until most of the ethanol evaporated.
The samples obtained by cooling to room temperature were
exposed in a hot air oven to completely vaporize the residual
ethanol. After vaporization, samples were milled to an extent
that most particles could pass through a 100-mesh sieve.
Solid dispersions of the Gelucire 44/14 and PEG 600 system
prepared by the fusion method were produced in two ways.
The first one was to heat the carrier to above their melting
point (about 60°C) and then evenly distribute nifedipine into
the carrier for 15 min. The other one was to mix the carrier
with nifedipine first and then melt them together at a temperature higher than that at which both drug and carrier would
melt. A fixed ratio (3 : 1) of these carrier systems (Gelucire
14/44, PEG 600, Gelucire 14/44/PEG 600 (4 : 1), and PVP/
PEG 6000 (1 : 3)) to nifedipine was prepared.
IV. Dissolution Studies
The dissolution profiles of nifedipine from samples (an
amount equivalent to 20 mg of nifedipine) were built at a
temperature of 37 ± 0.5°C and a stirring rate of 50 or 100
rpm by the paddle method (USP XXIII) in 900 mL of HCl
solution (pH 1.2) containing 1% w/v Tween 80. Samples were
automatically withdrawn at predetermined intervals (5, 10,
15, 20, 40, and 60 min) and analyzed under the following
HPLC conditions: a reverse -phase C18 column eluted by
mobile phase (methanol : water : acetic acid : triethylamine
= 65 : 35 : 1 : 0.03) at 1 mL/min and monitored at 280 nm(29).
The concentration of nifedipine was calculated based on a
calibration curve constructed during each run. An average
of at least three replicates was reported for each time point.
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The dissolution profile expressed as the cumulative release
(%) versus time was plotted for comparison. The exposure to
light was minimized during the process.

Results and Discussion
In an attempt to lower the fusion temperature for
preparing solid dispersions of nifedipine, thermal analysis
of nifedipine in the presence of several polymers in an incremental series of weight fractions was conducted. Figure 1
shows the DSC thermograms of pure nifedipine for the 1st
and 2nd heating runs. Thermograms of the 1st run indicated
that the melting point of pure nifedipine is approximately
173°C as an endothermic peak. However, an exothermic
peak around 109°C appeared in the 2nd run in addition to
the endothermic melting peak of nifedipine. The 2nd run of
the thermal analysis was executed after nifedipine had been
melted at 200°C and then rapidly cooled to 25°C so that
formation of amorphous form of nifedipine was expected.
The phase transition peak at 109°C was, therefore, attributed
to the transformation of the amorphous form of nifedipine to
the crystalline form.
Figure 2A (1st run) and 2B (2nd run) illustrated the
thermograms of nifedipine in the presence of PEG 6000
at percent weight fractions from 0 to 80%. Endothermic
peaks at around 62 and 173°C in the 1st run thermograms
represent the melting peaks of PEG 6000 and nifedipine,

respectively. Only a sharp peak at the melting point of PEG
6000 was observed in the 1st run for samples containing
0 - 40% nifedipine. However, the melting peak of nifedipine
gradually appeared in the 1st run thermograms when the
percent weight fraction of nifedipine went up to 60 - 80%.
In the thermograms of the 2nd run, the melting peak of PEG
6000 became broader and the peak height shifted to a lower
temperature with an increase in the percent weight fraction
of nifedipine from 0 to 40%. Similarly, the melting peak
of nifedipine did not appear in thermograms of the 2nd run
until the percent weight fraction was larger than 60%. The
broadness of the melting peak of nifedipine in the 2nd run
thermograms became more profound with increase in the
percent weight fraction of PEG 6000. Exothermic peaks, as
those in the 2nd run thermogram of pure nifedipine, also
appeared in the 2nd run thermograms when the percent
weight fraction of nifedipine exceeded 60%.
Theoretically, the broadness of the melting peak is
related to the amount of dissolved impurities, as indicated
in the van’t Hoff equation(30), which describes the melting of
a relatively pure material and the effect of impurities on the
shape of a DSC scan. The melting peak of nifedipine disappeared in thermograms of both runs. They disappeared in
samples with percent weight fractions of nifedipine from
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heated for the 1st (A) and 2nd run (B).
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0 - 40% and the extent of broadness of the PEG 6000
melting peak in the 2nd run thermograms increased with the
percent weight fraction of nifedipine. This indicated that
nifedipine was dissolved in the melted PEG 6000 during
the 1st run of heating, and the dissolved nifedipine appeared
to interfere with the melting of PEG 6000 during the 2nd
heating run. However, when the percent weight fraction of
nifedipine exceeded 60%, the melted PEG 6000 was not
soluble enough to completely dissolve nifedipine, resulting
in the appearance of the nifedipine melting peak in thermograms of the 1st run and the exothermic peak indicating the
transformation of the amorphous to the crystalline form of
nifedipine in the 2nd run thermograms. This suggests that
nifedipine is able to dissolve in fused PEG 6000 up to 60%
weight fraction with no need of heating temperature close to
the melting point of nifedipine.
Heating to approximately 110°C was tested to determine if it is sufficient to dissolve a 1 : 3 ratio of nifedipine to
PEG 6000 completely. For manufacturing, a solid dispersion
is preferred while prepared at a lower fusion temperature.
Nifedipine can be dissolved in melted PEG 6000 at a weight
percent of up to 60% so that it is not necessary to heat the
sample up to the melting point of nifedipine. This would
make preparation of solid dispersions by the fusion method
more practical.
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Figure 3A (1st run) and 3B (2nd run) demonstrated thermograms of nifedipine in the presence of PVP (K-12) with
incremental percent weight fractions of nifedipine. The 1st
run thermograms showed a broad peak with a maximum
near 90°C as the fusion peak of PVP. A broad to sharp peak
at a temperature close to 170°C was the fusion peak of nifedipine. During the 2nd run, the glass transition temperature
for PVP film reflected the film formation of the melted
PVP after cooling. This transition temperature dropped
as the percent weight fraction of nifedipine in the mixture
increased. In contrast, the melting peak of nifedipine disappeared from the 2nd run thermograms for all nifedipine/PVP
samples. The same phenomena were also observed when
PVP K-12 was replaced with PVP K-17, K-25 or K-30.
Solublization of nifedipine in the melted PVP did not
occur as fast as in melted PEG 6000, which caused a broad
to sharp peak of nifedipine in thermograms of samples
containing any percent weight fraction of nifedipine.
However, the formation of crystalline nifedipine from melted
nifedipine is completely prohibited by PVP after cooling
for any percent weight fraction of nifedipine, which was
evidenced as no exothermic peak for the transformation of
amorphous to crystalline forms of nifedipine, and no corresponding melting peak of nifedipine in the 2nd run thermograms. Thus, PVP must reach its melting temperature to fuse
nifedipine. Moreover, the crystallization of nifedipine from
its melted form during cooling can be completely abolished
by the fused PVP with the formation of a composite film.
The glass transition temperature of a polymer film is an
indicator of its tensile strength. The higher the glass transition temperature, the higher the tensile strength of a polymer
film. Figure 4 showed that the glass transition temperature
of PVP film increased with higher molecular weight of PVP
(K12 < K17 < K25 < K30), whereas increasing the fused
amount of nifedipine in the PVP films lowered the glass
transition temperature. In general, the higher the molecular
weight of a polymer, the higher the tensile strength. This
is consistent with the findings in Figure 4. In contrast, the
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Figure 3. DSC thermograms of nifedipine and PVP K-12 mixtures
heated for the 1st (A) and 2nd run (B).
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Figure 4. Glass transition temperature of PVP films with different K
values in the presence of various amounts of nifedipine.
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presence of fused nifedipine in the PVP films played the role
of impurity and weakened the structure of the polymer film,
which resulted in a decrease in the glass transition temperature and an increase in the fused amount of nifedipine in the
PVP films as predicted by the van’t Hoff equation.
The phase diagrams of nifedipine with Gelucire
44/14, PEG 600, and Gelucire 44/14-PEG 6000 (4 : 1) were
constructed. The diagrams showed that fusion temperatures
of 151.4, 157.5, and 158.8°C for nifedipine in the presence
of these hydrophilic carriers at nifedipine percent weight
fractions of 40, 60, and 50%, respectively. Although these
fusion temperatures are all lower than the melting point of
nifedipine, the amount of decrease in the fusion temperature
is no greater than that with PEG 6000, which could depress
the fusion temperature of nifedipine to approximately 110°C.
Solid dispersions of nifedipine with PEG 6000 or PVP
at a ratio of 1 : 3 were prepared by the fusion method as
described above. However, the dissolution of solid dispersions of the former were not profoundly enhanced, even
though nifedipine could be completely dissolved in melted
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Figure 5. Dissolution profiles of nifedipine from solid dispersions
prepared with PEG 6000 and various K values of PVP at a ratio of 3 : 1
with stirring at 50 (A) or 100 rpm (B).

PEG 6000 at a fusion temperature around 110°C, and the
amorphous form of nifedipine could be maintained after
cooling. In addition, the viscous nature of melted PVP,
which was heated to the melting temperature of nifedipine,
made the production of solid dispersions of nifedipine with
PVP difficult and impractical, even though the dissolution
of nifedipine was surely enhanced by PVP. A fusion-solvent
method was proposed as described in the Material and
Methods Section to prepare solid dispersions of nifedipine
with PEG 6000 and PVP at a ratio of 1 : 3 : 1. PEG 6000 was
used to lower the fusion temperature to a practical range.
PVP was dissolved in ethanol to reduce the viscosity of the
PVP and to uniformly mix it with the melted PEG 6000
while using less solvent.
The dissolution of nifedipine from solid dispersions
prepared with several grades of PVP of different molecular
weights (K12-K25) was compared with PEG 6000, by the
fusion/solvent method, and Gelucire 44/14 and PEG 600, by
the fusion method, at two different fusion temperatures. For
the PEG 6000 and PVP system, Figure 5 showed that the
smaller the K value of PVP, the faster the dissolution rate.
Increasing the stirring rate of dissolution also increased the
dissolution rate of nifedipine in all samples examined. PVP is
characterized by its viscosity in aqueous solution, expressed
as the K value, which is related to the molecular weight of
PVP. Due to their viscous natures, PEG 6000 and PVP could
enhance the adhesion among particles, which would make
them difficult to disperse in the dissolution medium. Dissolution would, thus, be reduced due to the minimized surface
area of particles. Expectedly, a lower K value of PVP with a
lower viscosity and lower molecular weight would improve
the dissolution of nifedipine from such a solid dispersion
prepared with it. Without exception, this effect was also
enhanced by a faster stirring rate.
Characteristics of the dissolution of nifedipine from the
Gelucire 44/14 and PEG 600 system were given in Figure 6.
The dissolution of mixtures prepared at higher temperature
was faster than those prepared at the melting point of Gelucire 44/14. This enhancing effect on the dissolution rate was
greater for Gelucire 44/14 than for PEG 600. The dissolution
of nifedipine from a mixture of Gelucire 44/14 and PEG 600
(4 : 1) was slower than that from the Gelucire 44/14 system
but faster than that from the PEG 600 system. In addition
to the formation of a readily soluble nifedipine during the
production of solid dispersions, the greater enhancement
of the dissolution rate of nifedipine by Gelucire 44/14 and
PEG 600 was also observed, possibly due to its wetting or
solubilizing effect as a hydrophilic surfactant (HLB = 14)
or solvent. As indicated by the phase diagrams, a fusion
temperature higher than 150°C would be necessary to melt
nifedipine crystals and transform them into an amorphous
form, which would enhance the dissolution rate. Without the
influence of fusion, nifedipine should dissolve at a similar
rate from solid dispersions prepared at two different fusion
temperatures. Nifedipine needs to be melted to enhance
the dissolution rate because of it being transformed into a
crystalline form with higher solubility. This explains why
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the transformation of the amorphous form of nifedipine.
PVP, however, is difficult to handle because of its viscosity
and uneven distribution. A fusion/solvent method is thus
proposed to eliminate this difficulty.
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Figure 6. Dissolution profiles of nifedipine from solid dispersions
prepared with Gelucire 44/14, PEG 6000, or Gelucire 44/14/PEG 6000
(4 : 1) fused at either the melting point of nifedipine (A) or Gelucire
44/14 (B).

the enhancement of the dissolution rate of nifedipine from
solid dispersions containing Gelucire 44/14 and PEG 600
is not solely due to their wetting or solubilizing effects.
The conclusion is that, dispersions must reach the fusion
temperature in order to enhance the dissolution rate of a
poorly soluble drug.

Conclusions
It was concluded that nifedipine could transform
into a crystalline form of higher solubility at lower fusion
temperature. This was found in the presence of PEG 6000,
which made the preparation of solid dispersions of nifedipine
by the fusion method more practical. This also demonstrated that it is critical to heat a poorly soluble drug to its
fusion temperature so that it can cool in a crystalline form
during the production of solid dispersions utilizing Gelcuire
44/14 and PEG 600 systems as carriers. PVP can prohibit
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